Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent.
The in vitro and in vivo activities of a new broad-spectrum triazole derivative, SCH 51048, against Blastomyces dermatitidis were evaluated. As determined by using the new National Committee for Clinical Laboratory Standards proposed standard for susceptibility testing of yeasts, SCH 51048 was the most active of the four agents tested in vitro against 13 strains of B. dermatitidis. In a well-described murine model of acute pulmonary blastomycosis, SCH 51048 was comparable to amphotericin B and at least 30 times more active than itraconazole. On the basis of these experiments, clinical evaluation of SCH 51048 for the use in treatment of human blastomycosis should proceed.
Sugar
A M
AM
Evans Memorial Department of Clinical Research, Boston University Medical Center Hospital, MA 02118, USA.
Picard
M
M
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy*; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; C094161:SCH 51048; D014230:Triazoles